Table 1.

Characteristics of the cancer patients with COVID-19 infection

PatientAgeSexCancer typeECOG performance statusCancer treatmentTime between last cancer treatment and first occurrence of COVID-19 symptoms (days)Management of COVID-19 infectionTime between first occurrence of COVID-19 symptoms and resumption of anti-cancer therapy (days)Last follow-up since COVID-19 infection (months)Outcomes
Patient 149MLung leiomyosarcoma with lung metastasis1Gemcitabine- dacarbazine
(Third line)		1Hospitalisation (7 days)
Oxygen therapy
Anticoagulation
Steroids		276Death of disease
Patient 221FLung adenocarcinoma (ALK rearrangement) with brain, bone, lung and liver metastasis1Brigatinib
(Third line)		0Ambulatory supervision with phone calls1012Alive
Patient 366FLung adenocarcinoma with lung metastasis2Weekly Paclitaxel
(Third line)		6Hospitalisation (5 days)
Oxygen therapy
Anticoagulation
Antibiotics		132Death of disease
Patient 471MLung adenocarcinoma with lung metastasis2Carboplatin- paclitaxel
(First line)		1Hospitalisation (12 days)
Oxygen therapy
Antibiotics
Tocilizumab		6312Alive
Patient 585FLung adenocarcinoma with node, pleural and lung metastasis1Gemcitabine- oxaliplatin
(Second line)		9Hospitalisation (6 days)
Oxygen therapy		5812Alive

  • ALK = anaplastic lymphoma kinase.